Ipilimumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Biliary Tract Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ipilimumab biosimilar LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ipilimumab biosimilar overview

Ipilimumab biosimilar (IBI-310) is under development for the treatment of advanced, recurrent or metastatic non-small-cell lung cancer(NSCLC), unresectable or relapsed or metastatic advanced Biliary tract cancer, metastatic solid tumors including advanced hepatocellular carcinoma, recurrent and metastatic nasopharyngeal carcinoma, liver cancer, cervical cancer, renal cell carcinoma, EBV-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and colon cancer. The drug candidate is administered through intravenous route. It acts by targeting cytotoxic T-lymphocyte protein 4 receptor (CTLA4). It was also under development for the treatment of metastatic melanoma, acral melanoma and metastatic colorectal adenocarcinoma.

Innovent Biologics overview

Innovent Biologics is a biopharmaceutical company that carries out the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company’s oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112 and IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311

For a complete picture of Ipilimumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.